ChiCTR2600131273 clinical trial report covering TARLATAMAB-DLLE, Phase 3, endpoints, sponsor, geography, readout timing and development white space.

NCT07794774 clinical trial report covering Berobenatide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.

NCT07796100 clinical trial report covering Zocilurtatug Pelitecan, Phase 3, endpoints, sponsor, geography, readout timing and development white space.

2026 Small Cell Lung Cancer clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.

2026 BD opportunity scan for Kissei Pharmaceutical Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach ration

2026 BD opportunity scan for JCR Pharmaceuticals Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rational

2026 BD opportunity scan for ImmunityBio, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Huahui Health Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Hangzhou DAC Biotechnology Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach r

2026 BD opportunity scan for Haisco Pharmaceutical Group Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach

2026 BD opportunity scan for Gilead Sciences, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Feldan Bio, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.